 The goal of this clinical research study is to learn if the combination of elotuzumab and revlimid also called lenalidomide can help to prevent multiple myeloma MM from coming back after patients have had an autologous stem cell transplant a transplant using participants own stem cells. The safety of this drug combination will also be studied. 